Intervacc signs an agreement for future filling and release of Strangvac.

Strangvac® is Intervacc’s vaccine against strangles, which is a very severe and contagious infection in the horse. Intervacc has previously signed an agreement with 3P Biopharmaceuticals in Pamplona, Spain for large-scale commercial production of the components in Strangvac®. The now signed agreement with Praxis Pharmaceuticals in Spain means that they will provide final formulation, filling of vials and packaging and final release of finished product.

“With this agreement, we have been assured that the entire manufacturing chain is in place for commercial production of Strangvac®. We look forward to performing testfilling of vials in the autumn which, among other things, is part of the work in the ongoing process of transfer of manufacturing technology. Moreover, the work is proceeding according to a set schedule for the final production of the validation batches required for the registration application scheduled to be submitted by the end of 2019″, says Jan-Ingmar Flock, CEO of Intervacc.

For more information please contact:
Jan-Ingmar Flock, CEO
Phone: +46-8-120 10 602 or +46-73-334 14 11

The information was submitted for publication, through the agency of the contact person set out above, at 13:00 CET on July 9, 2018.

About Praxis Pharmaceutical
Praxis Pharmaceutical is a European CDMO specialized in Drug Delivery, Formulation and ASEPTIC FILL FINISH, including LYOPHILIZATION of Biologics (proteins, Abs, etc.) and small molecules for clinical manufacturing and small/medium scale commercial manufacturing. Their brand new aseptic filling line can be considered as one of the best choices for small/medium size batches based on its superior process safety and flexibility, especially appropriate for high value products.

About 3P Biopharmaceuticals
3P Biopharmaceuticals is a leading CDMO specialized in the process development and GMP manufacturing of biologics and cell therapy products. Its extensive experience in projects covering all stages of the process development and GMP manufacturing in different expression systems, its flexibility and adaptation as well as innovative technology and its qualified team have made it a reference for the international biotech market. 3P has the support of an important group of investors: Cinfa Group. Cinfa Group is a holding of companies that handle different business lines in the world of health, with more than 50 years of experience in the biotech and pharma market. It’s flagship company, Laboratorios Cinfa, is a successful manufacturer that ranks first in terms of generic dispensed in Spanish retail pharmacies. More info:

About Intervacc
Intervacc AB (publ) is a company within the Biotechnology sector. The Company´s main area is to develop modern sub-unit vaccines against economically important bacterial infections, mainly within animal health. The company´s vaccine candidates are based on several years of research at Karolinska Institute and Swedish University of Agricultural Research where the foundation was laid for the company´s research and development work. The Intervacc share has been listed on the NASDAQ First North market since April 2017 with Eminova Fondkommission AB as Certified Adviser.